Obeticholic acid regulatory update

FDA granted Fast Track designation to Intercept’s obeticholic acid to treat primary biliary cirrhosis (PBC). By 1H15, Intercept plans to submit an NDA to FDA and an MAA to EMA for the oral farnesoid ...